> Detailanzeige

Cash, Brooks D.; Sharma, Amol; Walker, Anna; Laitman, Adam P.; Chang, Lin

Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo‐controlled trials in adults with severe constipation
  • Beteiligte: Cash, Brooks D.; Sharma, Amol; Walker, Anna; Laitman, Adam P.; Chang, Lin
  • Erschienen: Wiley, 2023
  • Erschienen in: Neurogastroenterology & Motility
  • Sprache: Englisch
  • DOI: 10.1111/nmo.14632
  • ISSN: 1350-1925; 1365-2982
  • Schlagwörter: Gastroenterology ; Endocrine and Autonomic Systems ; Physiology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Patients with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS‐C) often experience severe symptoms. The current aim was to evaluate plecanatide in adults with CIC or IBS‐C with severe constipation.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Data were analyzed post hoc from randomized, placebo‐controlled trials (CIC [<jats:italic>n =</jats:italic> 2], IBS‐C [<jats:italic>n =</jats:italic> 2]) of plecanatide 3 mg, 6 mg, or placebo administered for 12 weeks. Severe constipation was defined as no complete spontaneous bowel movements (CSBMs) and an average straining score ≥3.0 (CIC; 5‐point scale) or ≥8.0 (IBS‐C; 11‐point scale) during a 2‐week screening. Primary efficacy endpoints were durable overall CSBM responders (CIC: ≥3 CSBMs/week, plus increase from baseline of ≥1 CSBM/week, for ≥9 of 12 weeks, including ≥3 of the last 4 weeks) and overall responders (IBS‐C: ≥30% reduction from baseline in abdominal pain and ≥1 CSBM/week increase for ≥6 of 12 weeks).</jats:p></jats:sec><jats:sec><jats:title>Key Results</jats:title><jats:p>Severe constipation was observed in 24.5% (646/2639) and 24.2% (527/2176) of CIC and IBS‐C populations, respectively. The CIC durable overall CSBM response rate (plecanatide 3 mg, 20.9%; plecanatide 6 mg, 20.2%; placebo, 11.3%) and IBS‐C overall response rate (plecanatide 3 mg, 33.0%; plecanatide 6 mg, 31.0%; placebo, 19.0%) were significantly greater with plecanatide versus placebo (<jats:italic>p</jats:italic> ≤ 0.01 for all). Median time to first CSBM in CIC and IBS‐C populations were significantly shorter with plecanatide 3 mg versus placebo (<jats:italic>p</jats:italic> = 0.01 for both).</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Inferences</jats:title><jats:p>Plecanatide was effective in the treatment of severe constipation in adults with CIC or IBS‐C.</jats:p></jats:sec>